Scholarlink

Purpose of Review <p>Guideline-concordant locoregional therapy (LRT) for inflammatory breast cancer (IBC) consists of modified radical mastectomy (MRM) after neoadjuvant systemic therapy and post-mastectomy radiotherapy (PMRT). Despite advances in systemic therapy, de-escalation of LRT remains unsupported. This review synthesizes modern data affirming guideline-concordant LRT to optimize locoregional control and survival.</p> Recent Findings <p>Utilization of the validated IBC Scoring System can facilitate prompt and accurate diagnosis, yet adherence to life-saving guideline-concordant care is declining. Optimal LRT consists of MRM with resection of involved skin and PMRT delivering an equivalent dose in 2&#xa0;Gy (Gy) fractions (EQD2) ≥ 60&#xa0;Gy to the chest wall and involved, unresected lymph nodes. Adherence to guideline-concordant LRT combined with modern systemic therapies is associated with improved survival.</p> Summary <p>With earlier diagnosis and more effective systemic treatments, the potential for LRT to achieve durable remission is amplified. Guideline-concordant LRT remains essential to eradicate locoregional disease and maximize the curative potential of trimodality therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Contemporary Locoregional Therapy for Inflammatory Breast Cancer: Don’t De-Escalate Off Protocol

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月23日

查看全文
  • Chelain R. Goodman,
  • Susie X. Sun,
  • Anthony Lucci,
  • Michael C. Stauder,
  • Wendy A. Woodward

摘要

Purpose of Review

Guideline-concordant locoregional therapy (LRT) for inflammatory breast cancer (IBC) consists of modified radical mastectomy (MRM) after neoadjuvant systemic therapy and post-mastectomy radiotherapy (PMRT). Despite advances in systemic therapy, de-escalation of LRT remains unsupported. This review synthesizes modern data affirming guideline-concordant LRT to optimize locoregional control and survival.

Recent Findings

Utilization of the validated IBC Scoring System can facilitate prompt and accurate diagnosis, yet adherence to life-saving guideline-concordant care is declining. Optimal LRT consists of MRM with resection of involved skin and PMRT delivering an equivalent dose in 2 Gy (Gy) fractions (EQD2) ≥ 60 Gy to the chest wall and involved, unresected lymph nodes. Adherence to guideline-concordant LRT combined with modern systemic therapies is associated with improved survival.

Summary

With earlier diagnosis and more effective systemic treatments, the potential for LRT to achieve durable remission is amplified. Guideline-concordant LRT remains essential to eradicate locoregional disease and maximize the curative potential of trimodality therapy.